<DOC>
	<DOCNO>NCT01347216</DOCNO>
	<brief_summary>In view manifold option mono- combination therapy emerge patient pulmonary ( arterial ) hypertension ( PH/PAH ) , control clinical trial provide part information need optimal management . In order gather adequate data PAH/PH treatment routine clinical care , ongoing COMPERA registry prospectively document consecutive patient newly initiate treatment PAH/PAH since May 2007 . The internet-based registry fulfills high quality standard several measure ( plan minimum centre contribution least 10 patient per year , automate plausibility check data entry , query , monitor source data verification &gt; 50 % participate center ) . It apply , among purpose , quality assurance : individual center confidentially compare result combine outcome center recommendation guideline . It expect register contributes optimization specific drug therapy PAH PH . Since July 2013 , also child age document ( COMPERA-KIDS ) .</brief_summary>
	<brief_title>COMPERA / COMPERA-KIDS</brief_title>
	<detailed_description>COMPERA report current comprehensive data - Demographics clinical course incident prevalent PAH PH patient - Patient outcomes include survival , subgroup , treatment strategy factor - Clinical predictor short-term long-term clinical outcome - Relationship PAH medication patient outcomes - Temporal trend treatment outcomes newly diagnose patient - The state implementation current PAH guideline - Evolving research need PAH community - Patients PAH associate congenital heart disease Eisenmenger physiology receive specific drug therapy PAH ( `` COMPERA-Eisenmenger '' , state amendment date 23 . January 2012 ) . - Children age PH PAH ( Dana Point group ) , state amendment date 1 June 2013 ( `` COMPERA-KIDS '' ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<criteria>All age group ( amendment date 1 June 2013 ) Written informed consent Pulmonary hypertension ( PH ) either PAH : idiopathic form ( IPAH ) PAH associate connective tissue disease ( PAHCTD ) , congenital heart defect ( PAHCHD ) , HIV infection ( PAHHIV ) , portopulmonary form Chronic thromboembolic PH ( CTEPH ) PH leave heart disease ( isolate diastolic dysfunction ; systolic dysfunction , ) PH pulmonary disease ( chronic obstructive pulmonary disease ; interstitial fibrosis , etc . ) `` Relative PH '' CHD cavopulmonary anastomosis Fontantype surgery , even without classical pulmonary pressure criterion PH . Newly initiate ( i.e . maximum 3 month documentation first time ) therapy endothelin receptor antagonist ( ERA ) , phoshodiesterase5 ( PDE5 ) inhibitor , soluble guanylate cyclase ( sGC ) stimulators prostacyclins mono combination therapy . Exceptions : PAHCHD patient include maintenance newly initiate PAH therapy ( 3month rule dose apply ) . PAHCHD patient severe pulmonary vascular disease ( e.g . Eisenmenger physiology ) irrespective treatment PAH drug eligible inclusion , . Patients maintenance therapy , i.e . previous treatment ERA/ PDE5 inhibitor/prostacyclin/sGC stimulator drug longer 3 month documentation first time ( exception : PAHCHD patient ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Drug treatment</keyword>
	<keyword>Treatment pathway</keyword>
	<keyword>Clinical routine</keyword>
	<keyword>Registry</keyword>
	<keyword>Treatment outcome</keyword>
	<keyword>Endothelin receptor antagonist</keyword>
	<keyword>Phosphodiesterase-V inhibitor</keyword>
	<keyword>Prostanoid</keyword>
	<keyword>Sildenafil</keyword>
	<keyword>Bosentan</keyword>
	<keyword>Macitentan</keyword>
	<keyword>Sitaxentan</keyword>
	<keyword>Ambrisentan</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Epoprostenol</keyword>
	<keyword>Treprostinil</keyword>
	<keyword>Iloprost</keyword>
	<keyword>Infusion pump</keyword>
	<keyword>Riociguat</keyword>
	<keyword>soluble guanylate cyclase stimulator</keyword>
	<keyword>Quality life</keyword>
	<keyword>Patient-related outcome</keyword>
	<keyword>Economic model</keyword>
	<keyword>Adverse event</keyword>
	<keyword>Safety</keyword>
	<keyword>Combination therapy</keyword>
	<keyword>Internet</keyword>
	<keyword>Europe</keyword>
	<keyword>Australia</keyword>
	<keyword>Japan</keyword>
	<keyword>Eisenmenger</keyword>
	<keyword>Adults</keyword>
	<keyword>Children</keyword>
	<keyword>Selexipag</keyword>
</DOC>